PA lawmakers push to make ivermectin available OTC; top infection control groups urge hospitals to strengthen prevention programs; AI urine test to detect prostate cancer early – Morning Medical Update

Author(s):

Austin Littrell

Fact checked by:

Keith A. Reynolds

Key Takeaways

Pennsylvania's proposed bill for over-the-counter ivermectin access highlights ongoing debate over its use for COVID-19, despite FDA disapproval.
Infection prevention and control programs in U.S. healthcare facilities require urgent upgrades, as emphasized by a new multisociety position paper.
AI-driven urine tests developed by Karolinska Institutet researchers could revolutionize prostate cancer screening by offering early and accurate detection.

The top news stories in medicine today.

PA lawmakers push to make Ivermectin available over the counter

State Sen. Doug Mastriano (R-Pennsylvania) has introduced a bill to allow over-the-counter sales of ivermectin, joining a growing national movement. Although ivermectin is FDA-approved for treating parasitic infections like scabies and river blindness, it has not been approved for COVID-19 treatment — despite lingering public debate. Supporters argue easier access will empower patients, especially in rural areas, but health experts warn that misuse could carry risks and stress that decisions about its use should involve medical guidance. Similar laws have already passed in Idaho, Arkansas and Tennessee.

Top infection control groups urge hospitals to strengthen prevention programs

A new multisociety position paper led by the Society for Healthcare Epidemiology of America (SHEA) warns that infection prevention and control (IPC) programs in U.S. health care facilities need urgent upgrades. Released today, the paper calls on hospitals and regulators to prioritize IPC as essential to patient safety and operational stability, not just regulatory compliance. Key recommendations include better leadership structures, stronger staffing and direct executive support — lessons underscored by gaps exposed during the COVID-19 pandemic.

AI-driven urine test shows promise for early detection of prostate cancer

Researchers at Karolinska Institutet have identified a new set of urine-based biomarkers that could detect prostate cancer earlier and more accurately than current PSA tests. Using AI to analyze tumor gene activity from nearly 2,000 patients, the team found that a simple, non-invasive urine sample could reveal both the presence and severity of prostate cancer. Large clinical trials are now planned to validate the findings and potentially transform future screening methods.